JP2023512456A5 - - Google Patents

Info

Publication number
JP2023512456A5
JP2023512456A5 JP2022542692A JP2022542692A JP2023512456A5 JP 2023512456 A5 JP2023512456 A5 JP 2023512456A5 JP 2022542692 A JP2022542692 A JP 2022542692A JP 2022542692 A JP2022542692 A JP 2022542692A JP 2023512456 A5 JP2023512456 A5 JP 2023512456A5
Authority
JP
Japan
Prior art keywords
glycine
methionine
seq
combination
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022542692A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023512456A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/013074 external-priority patent/WO2021146191A1/en
Publication of JP2023512456A publication Critical patent/JP2023512456A/ja
Publication of JP2023512456A5 publication Critical patent/JP2023512456A5/ja
Pending legal-status Critical Current

Links

JP2022542692A 2020-01-13 2021-01-12 Il-7タンパク質と二重特異性抗体の組み合わせで腫瘍を治療する方法 Pending JP2023512456A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202062960593P 2020-01-13 2020-01-13
US62/960,593 2020-01-13
US202063108760P 2020-11-02 2020-11-02
US63/108,760 2020-11-02
US202063109475P 2020-11-04 2020-11-04
US63/109,475 2020-11-04
PCT/US2021/013074 WO2021146191A1 (en) 2020-01-13 2021-01-12 Method of treating a tumor with a combination of il-7 protein and a bispecific antibody

Publications (2)

Publication Number Publication Date
JP2023512456A JP2023512456A (ja) 2023-03-27
JP2023512456A5 true JP2023512456A5 (https=) 2024-01-22

Family

ID=74562022

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022542692A Pending JP2023512456A (ja) 2020-01-13 2021-01-12 Il-7タンパク質と二重特異性抗体の組み合わせで腫瘍を治療する方法

Country Status (8)

Country Link
US (1) US20230057939A1 (https=)
EP (1) EP4090430A1 (https=)
JP (1) JP2023512456A (https=)
KR (1) KR20220150274A (https=)
CN (1) CN114945409A (https=)
AU (1) AU2021207586A1 (https=)
IL (1) IL294663A (https=)
WO (1) WO2021146191A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112022003300A2 (pt) * 2019-09-04 2022-05-24 Genexine Inc Método para aumentar a contagem de linfócitos usando proteína de fusão de il-7 em tumores
US20250319127A1 (en) * 2021-10-29 2025-10-16 University Of Virginia Patent Foundation Bispecific antibodies

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4044126A (en) 1972-04-20 1977-08-23 Allen & Hanburys Limited Steroidal aerosol compositions and process for the preparation thereof
GB1429184A (en) 1972-04-20 1976-03-24 Allen & Hanburys Ltd Physically anti-inflammatory steroids for use in aerosols
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4925648A (en) 1988-07-29 1990-05-15 Immunomedics, Inc. Detection and treatment of infectious and inflammatory lesions
JP3485184B2 (ja) 1989-07-14 2004-01-13 アメリカン サイアナミド カンパニー インターロイキン含有安定ワクチン組成物
US5585112A (en) 1989-12-22 1996-12-17 Imarx Pharmaceutical Corp. Method of preparing gas and gaseous precursor-filled microspheres
IT1246382B (it) 1990-04-17 1994-11-18 Eurand Int Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon
US5543390A (en) 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
US5364612A (en) 1991-05-06 1994-11-15 Immunomedics, Inc. Detection of cardiovascular lesions
US6010715A (en) 1992-04-01 2000-01-04 Bertek, Inc. Transdermal patch incorporating a polymer film incorporated with an active agent
US6024975A (en) 1992-04-08 2000-02-15 Americare International Diagnostics, Inc. Method of transdermally administering high molecular weight drugs with a polymer skin enhancer
US6274552B1 (en) 1993-03-18 2001-08-14 Cytimmune Sciences, Inc. Composition and method for delivery of biologically-active factors
US5985307A (en) 1993-04-14 1999-11-16 Emory University Device and method for non-occlusive localized drug delivery
US5523092A (en) 1993-04-14 1996-06-04 Emory University Device for local drug delivery and methods for using the same
US6004534A (en) 1993-07-23 1999-12-21 Massachusetts Institute Of Technology Targeted polymerized liposomes for improved drug delivery
US5759542A (en) 1994-08-05 1998-06-02 New England Deaconess Hospital Corporation Compositions and methods for the delivery of drugs by platelets for the treatment of cardiovascular and other diseases
US5660854A (en) 1994-11-28 1997-08-26 Haynes; Duncan H Drug releasing surgical implant or dressing material
US5983134A (en) 1995-04-23 1999-11-09 Electromagnetic Bracing Systems Inc. Electrophoretic cuff apparatus drug delivery system
US6316652B1 (en) 1995-06-06 2001-11-13 Kosta Steliou Drug mitochondrial targeting agents
US6167301A (en) 1995-08-29 2000-12-26 Flower; Ronald J. Iontophoretic drug delivery device having high-efficiency DC-to-DC energy conversion circuit
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
US6039975A (en) 1995-10-17 2000-03-21 Hoffman-La Roche Inc. Colon targeted delivery system
TW345603B (en) 1996-05-29 1998-11-21 Gmundner Fertigteile Gmbh A noise control device for tracks
US7118754B1 (en) 1996-07-30 2006-10-10 Transgene S.A. Pharmaceutical composition for treating papillomavirus tumors and infection
US5985317A (en) 1996-09-06 1999-11-16 Theratech, Inc. Pressure sensitive adhesive matrix patches for transdermal delivery of salts of pharmaceutical agents
JP2000508339A (ja) 1996-10-01 2000-07-04 シーマ・ラブス・インコーポレイテッド 味隠蔽マイクロカプセル組成物及び製造方法
PT904392E (pt) 1996-10-17 2001-06-29 Oxford Biomedica Ltd Vectores retrovirais
GB9621680D0 (en) 1996-10-17 1996-12-11 Oxford Biomedica Ltd Lentiviral vectors
GB9622500D0 (en) 1996-10-29 1997-01-08 Oxford Biomedica Ltd Therapeutic gene
US6131570A (en) 1998-06-30 2000-10-17 Aradigm Corporation Temperature controlling device for aerosol drug delivery
US5860957A (en) 1997-02-07 1999-01-19 Sarcos, Inc. Multipathway electronically-controlled drug delivery system
US6120751A (en) 1997-03-21 2000-09-19 Imarx Pharmaceutical Corp. Charged lipids and uses for the same
US6730512B2 (en) 1997-04-09 2004-05-04 Amdl, Inc. Combination immunogene therapy
US6060082A (en) 1997-04-18 2000-05-09 Massachusetts Institute Of Technology Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery
US5948433A (en) 1997-08-21 1999-09-07 Bertek, Inc. Transdermal patch
CN1152673C (zh) 1997-10-28 2004-06-09 坂东化学株式会社 皮肤贴附药片及其基片的制造方法
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
US6048736A (en) 1998-04-29 2000-04-11 Kosak; Kenneth M. Cyclodextrin polymers for carrying and releasing drugs
JP2002526079A (ja) 1998-09-21 2002-08-20 シェーリング コーポレイション ヒトインターロイキン−b50、治療的使用
US6271359B1 (en) 1999-04-14 2001-08-07 Musc Foundation For Research Development Tissue-specific and pathogen-specific toxic agents and ribozymes
US6256533B1 (en) 1999-06-09 2001-07-03 The Procter & Gamble Company Apparatus and method for using an intracutaneous microneedle array
US6261595B1 (en) 2000-02-29 2001-07-17 Zars, Inc. Transdermal drug patch with attached pocket for controlled heating device
CA2404479A1 (en) 2000-03-30 2001-10-11 University Of Connecticut Hybrid cytokine of il-7 and .beta.-chain of hepatocyte growth factor
US6989452B2 (en) 2001-05-31 2006-01-24 Medarex, Inc. Disulfide prodrugs and linkers and stabilizers useful therefor
EP1391513A1 (en) 2002-08-08 2004-02-25 Cytheris IL-7 drug substance, IL-7 comprising composition, preparation and uses thereof
US20050054054A1 (en) 2002-11-12 2005-03-10 Foss Francine M. Interleukin-7 molecules with altered biological properties
ES2305886T3 (es) 2003-12-30 2008-11-01 Merck Patent Gmbh Proteinas de fusion de il-7 con porciones de anticuerpo, su preparacion y su empleo.
JP4806680B2 (ja) 2004-05-19 2011-11-02 メダレックス インコーポレイテッド 自己犠牲リンカー及び薬剤複合体
US7691962B2 (en) 2004-05-19 2010-04-06 Medarex, Inc. Chemical linkers and conjugates thereof
RU2437893C2 (ru) 2004-12-09 2011-12-27 Мерк Патент Гмбх Варианты il-7 со сниженной иммуногенностью
US7714016B2 (en) 2005-04-08 2010-05-11 Medarex, Inc. Cytotoxic compounds and conjugates with cleavable substrates
EP1746161A1 (en) 2005-07-20 2007-01-24 Cytheris Glycosylated IL-7, preparation and uses
EP2354163A3 (en) 2005-09-26 2013-04-24 Medarex, Inc. Conjugates of duocarmycin and anti-CD70 or anti-PSMA antibodies
RS52100B (sr) 2005-10-26 2012-06-30 Medarex, Inc. Postupci i jedinjenja za pripremu analoga cc-1065
WO2007059404A2 (en) 2005-11-10 2007-05-24 Medarex, Inc. Duocarmycin derivatives as novel cytotoxic compounds and conjugates
GB2434578A (en) 2006-01-26 2007-08-01 Univ Basel Transgenic animals
TWI412367B (zh) 2006-12-28 2013-10-21 梅達雷克斯有限責任公司 化學鏈接劑與可裂解基質以及其之綴合物
AR065404A1 (es) 2007-02-21 2009-06-03 Medarex Inc Conjugados farmaco-ligando, los que se unen a citotoxinas potentes, composicion farmaceutica que los contienen y su uso para retardar o detener el crecimiento de un tumor en un mamifero
ES2623925T3 (es) 2007-05-30 2017-07-12 Postech Academy-Industry- Foundation Proteínas de fusión de inmunoglobulina
GB0815216D0 (en) 2008-08-21 2008-09-24 Asterion Ltd Interleukin
EP2556087A1 (en) 2010-04-09 2013-02-13 Novozymes Biopharma DK A/S Albumin derivatives and variants
US9505826B2 (en) 2010-12-22 2016-11-29 Teva Pharmaceuticals Australia Pty Ltd Modified antibody with improved half-life
SG11201404751UA (en) 2012-02-09 2014-09-26 Chugai Pharmaceutical Co Ltd Modified fc region of antibody
CN114853873B (zh) * 2015-06-11 2025-01-28 格纳西尼有限公司 经修饰的白细胞介素-7蛋白及其用途
WO2017062035A1 (en) 2015-10-09 2017-04-13 Abt Holding Company Methods for enhancing proliferation of t regulatory cells
KR102386735B1 (ko) 2015-11-06 2022-04-14 주식회사 제넥신 변형된 인터루킨-7 융합 단백질의 제형
US11072666B2 (en) * 2016-03-14 2021-07-27 Chugai Seiyaku Kabushiki Kaisha Cell injury inducing therapeutic drug for use in cancer therapy
EP3608341A4 (en) * 2017-04-01 2021-01-06 Beijing Hanmi Pharmaceutical Co., Ltd. HETERODIMER BIS SPECIFIC ANTI-PD-1 / ANTI-HER2 ANTIBODIES WITH NATURAL ANTIBODY STRUCTURE AND PRODUCTION OF IT
AR112257A1 (es) 2017-06-21 2019-10-09 Gilead Sciences Inc Anticuerpos multiespecíficos dirigidos al vih-1 gp120 y cd3 humana, composiciones que los comprende, ácido nucleico, vector y célula huésped relacionados, método para producirlos, método para detectar células que expresan gp120 y cd3, kit de anticuerpos, fragmentos de anticuerpo que se une a gp120 y método para producirlos
EP3858369A4 (en) * 2018-09-26 2022-07-20 Astellas Pharma Inc. Cancer therapy where oncolytic vaccinia virus and immune checkpoint inhibitor are used in combination, and pharmaceutical composition and combination drug used therein

Similar Documents

Publication Publication Date Title
May et al. Advances in bispecific biotherapeutics for the treatment of cancer
US20260102510A1 (en) Conditioning for in vivo immune cell engineering
Müller et al. Bispecific antibodies for cancer immunotherapy: Current perspectives
CN104379601B (zh) 双特异性抗体分子和抗原-转染的t-细胞以及它们在医药中的用途
US10611814B2 (en) Universal chimeric antigen expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders
Maruani et al. A plug-and-play approach for the de novo generation of dually functionalized bispecifics
JP2022545439A5 (https=)
Thakur et al. Cancer therapy with bispecific antibodies: Clinical experience
Moon et al. Development of bispecific antibody for cancer immunotherapy: focus on T cell engaging antibody
AU2019286554A1 (en) Reversed universal chimeric antigen receptor expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders
WO2021144315A9 (en) Conjugates of antibodies an immune cell engagers
US20240197931A1 (en) Radioimmunotherapy directed to ccr8 for depletion of tumor infiltrating regulatory t cells
TW201842182A (zh) 具抗原專一性的t細胞及其用途
AU2018295119A1 (en) Multi-specific antibodies and methods of making and using thereof
JP2023550172A (ja) Nkg2aを標的にする抗体及びその使用
Guo et al. Revolutionizing cancer immunotherapy: unleashing the potential of bispecific antibodies for targeted treatment
US20180256744A1 (en) Chimeric antigen receptor to which anti-cotinine antibody is linked, and use thereof
JP2022512891A5 (https=)
JP2024519335A (ja) がん免疫療法のための投薬レジメン
JP2023512456A5 (https=)
Kelly et al. Tumor targeting by a multivalent single-chain Fv (scFv) anti-Lewis Y antibody construct
JP2023512657A5 (https=)
Wang et al. Retargeting T cells for HER2-positive tumor killing by a bispecific Fv-Fc antibody
Ren‐Heidenreich et al. Redirected T‐cell cytotoxicity to epithelial cell adhesion molecule‐overexpressing adenocarcinomas by a novel recombinant antibody, E3Bi, in vitro and in an animal model
Li et al. Highlights of 2019 protein engineering summit (PEGS) in Boston, USA: advancing antibody-based cancer therapies to the clinic